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Abstract
Recent advances in the development of sequencing technologies provide researchers with unprecedented
possibilities for genetic analyses. In this review, we will discuss the history of genetic studies and the progress
driven by next-generation sequencing (NGS), using complex inflammatory bowel diseases as an example. We focus
on the opportunities, but also challenges that researchers are facing when working with NGS data to unravel the
genetic causes underlying diseases.
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Background
Studies of human genetic variation using DNA sequen-
cing have undergone an extraordinary development from
their introduction over 40 years ago up to current
technologies, which allow for a human genome to be
sequenced and analyzed within a matter of days at
consumable costs of approximately 1000 USD. The first
widely used method was developed by the British
chemist Frederick Sanger in the 1970s [1] and he
received the Nobel prize in 1980. “Sanger sequencing”
relies on nucleotide-specific chain-terminating inhibitors
to identify the sequence of a specific fragment of DNA.
The method was continuously refined over the years and
incorporated in the first generation of automated se-
quencers. Sanger sequences show very high accuracy but
are restricted to a single DNA fragment at a time and a
maximum sequence length of 1000 bp. In addition to
the low throughput, high costs render this technology
unsuitable for routine large scale sequencing projects.
The largest effort using the Sanger technique was the
Human Genome Project with the goal of identifying the
complete sequence of the human genome [2], which is
in essence based on different donors from Buffalo
(New York, USA) [3, 4]. Completion of the project took
over a decade (1990–2003), involved more than 20 insti-
tutes all over the world and cost nearly 3 billion dollars.
Still, for many years, Sanger sequencing was the prevailing
technique to identify causative mutations in monogenic
diseases. However, the limitations of the technology meant
that finding the one gene responsible for a disease was
tedious work. Rather than performing large-scale, indis-
criminate sequencing, numerous experiments were often
necessary to narrow down candidate regions from
microsatellite-based linkage studies and pinpoint to one
or a few candidate genes that would then be sequenced. In
most cases, these experiments required samples from
large pedigrees with several affected individuals to suc-
cessfully identify candidate regions small enough for fur-
ther analysis. These issues are further amplified in the
study of genetically heterogeneous diseases with causative
variants in a number of genes or very large genes, as well
as diseases that do not follow a Mendelian inheritance pat-
tern, but instead have a complex genetic background in-
volving tens to hundreds of genes. The common disease-
common variant hypothesis assumes that a large part of
the heritability of these complex diseases can be attributed
to variants with a minor allele frequency above 1% (single
nucleotide polymorphisms, SNPs) in the general popula-
tion, each variant having a small additive or multiplicative
effect on the disease phenotype. Addressing questions as
complex as these clearly required novel approaches.
However, it was not until the introduction of high-
throughput genotyping in the early 2000s, enabling the
interrogation of several hundred thousand to millions of
genotypes in thousands of cases and controls [5], that
genome-wide association studies (GWAS) became a* Correspondence: a.franke@mucosa.de
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reality. For the first time a quick and unbiased screening
of SNPs throughout the whole genome was possible,
thereby facilitating the detection of susceptibility regions
for complex diseases. What followed can be referred to
as the “GWAS era”, with genome-wide case-control
association studies carried out for numerous complex
diseases, identifying more than 25,000 significantly
disease-associated genetic loci until today [6]. GWAS
studies primarily focused on common SNPs, excluding
rare variants. Later approaches like Illumina’s human ex-
ome genotyping array [7] shifted the focus to include rare,
exonic variants. However, it soon became clear that
genotyping efforts alone were not sufficient to completely
uncover the genetics behind complex diseases [8].
The release of the first “next-generation” sequencing in-
struments (NGS; see [9] for an overview) in the mid-2000s
led to a first revolution in disease study, offering vastly im-
proved speed at significantly lower cost - enabling the gen-
eration of a whole human genome sequence in a matter of
weeks for 10,000 USD by 2011 [10]. In addition to price
and performance, the new sequencing technology also
proved to compensate for some of the technical weak-
nesses of the older sequencing and genotyping technolo-
gies, allowing for the genome-wide detection of variants,
including novel ones, at a low cost. However, despite the
immense drop in sequencing costs for a human genome,
large-scale sequencing projects were still costly and there-
fore not yet carried out for thousands of samples as rou-
tinely done in GWAS.
In 2007, Craig Venter published the first diploid genome
sequence of a single individual, which was created using
the gold-standard Sanger sequencing technology, and
which is perhaps still among the most accurate and best-
annotated human genomes released to the public domain
[11]. However, DNA materials of the donor are, to our
knowledge, not available to the public for benchmarking
and follow-up studies. This year however, the academic
Genome in a Bottle Consortium provided extensive NGS
data on seven genomes, including two trios, which serve
as open benchmarking data and materials [12].
The next breakthrough for NGS in human genomics ar-
rived with the introduction of targeted enrichment
methods, allowing for selective sequencing of regions of
interest [13] and thereby dramatically reducing the
amount of sequences that needed to be generated. The ap-
proach is based on a collection of DNA or RNA probes
representing the target sequences in the genome, which
can bind and extract the DNA fragments originating from
these targeted regions. Whole exome sequencing (WES),
which enables sequencing of all protein-coding regions in
the human genome (the exome) quickly became the most
widely used targeted enrichment method, especially for
monogenic (“Mendelian”) diseases. This approach enabled
the detection of both exonic (coding) as well as splice-site
variants, while requiring only approximately 2% of se-
quencing “load” compared to whole genome sequencing
(WGS). The unbiased analysis of all genes eliminates the
need for a time-consuming selection of candidate genes
prior to sequencing. It has been estimated that the exome
harbors about 85% of mutations with large effects on
disease-related traits [14]. In addition, exonic mutations
were shown to cause the majority of monogenic diseases
[15], with missense and nonsense mutations alone ac-
counting for approximately 60% of disease mutations [16].
While these numbers may be in part biased by the
difficulty of identifying disease-causing mutations in non-
coding regions, the success of exome sequencing studies
for monogenic diseases confirms its advantages. In the
years following its introduction, exome sequencing led to
a vast increase in the identification of Mendelian disease
genes [17, 18]. This is reflected for example in almost
2000 new entries in OMIM since 2008 (current total:
4787), describing the molecular basis of a particular
phenotype.
Current large-scale genome and exome sequencing
projects [19–22] have not only provided crucial informa-
tion on variant frequencies in different populations, but
have also shown that a human genome typically contains
an estimated 100 genuine loss-of-function variants,
completely inactivating around 20 genes [23]. Therefore,
sequencing of healthy individuals or representative po-
pulation samples can also lead to important insights into
disease. Focusing on seemingly “healthy human knock-
outs” can aid in detecting the true effects of variants
previously assumed to be disease-causing [24] and ex-
ploring gene function in general, thus elucidating the
“resilience” phenomenon further [25].
In recent years, NGS has also been increasingly ap-
plied for addressing pharmacogenomic research ques-
tions. It is not only possible to detect genetic causes that
explain why some patients do not respond to a certain
drug, but also try to predict a drug’s success based on
genetic information [26]. Certain genetic variants can
affect the activity of a particular protein and these can
be used to estimate the probable efficacy and toxicity of
a drug targeting such a protein [27]. NGS therefore has
applications far beyond finding disease-causing variants.
For inflammatory bowel diseases (IBD) we refer to the
exhaustive pharmacogenomics review of Katsanos and
colleagues [28].
Progress of genetic research for common complex
diseases
Some of the diseases that profited immensely from
GWAS are inflammatory bowel diseases. Together with
ulcerative colitis (UC), Crohn’s disease (CD) is one of
the two main sub-phenotypes of IBD. IBD are chronic,
relapsing disorders involving inflammation of the
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gastrointestinal tract, sometimes accompanied by extra-
intestinal manifestations. The disease onset can occur at
any age, but the peak for CD as well as UC is in early
adulthood (approximately 25 to 35 years of age). In the
clinic, symptoms include chronic flare-ups of inflamma-
tion, abdominal cramping pain as well as diarrhea and
weight loss, thereby greatly affecting the quality of life of
patients. In Europe, an estimated 1.4 million people suf-
fer from CD [29] but as of yet, there is no known cure
and the current treatment is solely aimed at controlling
the symptoms. The current consensus is that IBD is
caused by the complex interplay of an overly active im-
mune system and environmental triggers (such as bac-
terial infections, dietary habits or smoking) in genetically
susceptible individuals [30, 31]. The strong genetic com-
ponent, especially for CD, is reflected by familial cluster-
ing of disease occurrence and a concordance of 35% in
monozygotic but only 3% in dizygotic twin pairs [32].
The relative risk for developing IBD is estimated to be
15 times higher for first degree relatives of an IBD
patient than in the general population [33].
Due to the complex nature of IBD, genetic research
focused on the identification of genetic risk factors that
increase the susceptibility to the disease, typically com-
mon SNP alleles that are significantly more frequent in
patients than in healthy controls. The aforementioned
methods have all contributed to the discovery of genetic
risk factors for IBD in the past. Genome-wide linkage and
candidate gene studies during the late 1990s were able to
identify the first susceptibility loci for IBD through
positional cloning and candidate gene analysis. The first
susceptibility gene to be identified for CD was NOD2
[34, 35], encoding for a member of the cytoplasmic
nucleotide-binding oligomerization domain (NOD)-like
receptor (NLR) protein family. Over the years, several
association studies added significantly to the number of
identified loci [36, 37], followed by meta-analyses which
combined the data of several individual GWAS-studies
from all over the world. The larger sample sizes led to
more statistical power and eventually to the discovery of
numerous additional susceptibility loci [38–40]. Today,
more than 200 loci have been identified for IBD [41] and
have highlighted some key pathways involved in the
etiology of IBD. Figure 1 illustrates the success of
hypothesis-free genome-wide studies. For example, our
group first unveiled the link of autophagy to IBD by iden-
tifying ATG16L1 in a genome-wide candidate SNP screen
[42]. Before, NOD2 had been identified as the first and so
far best-replicated Crohn’s disease susceptibility gene
through two independent studies [34, 35]. Gene identifica-
tion is then ideally followed by numerous validation and
in particular functional/mechanistic studies of the respect-
ive candidate genes. Bringing disease genes on the radar
of the research community leads to further studies, then
Fig. 1 Number of PubMed citations for ATG16L1, NOD2, IL23R, HLA/MHC, GWAS and autophagy in combination with “inflammatory bowel
disease”, “Crohn’s disease” OR “ulcerative colitis” from the years 1997–2015 depicting a steep increase of follow-up studies for genes and pathways
after discovery. Interestingly, the HLA/MHC association signal in IBD has been known for a long time, however, studies for this locus in IBD are rarer
and no increase can be observed. We think that this region is understudied, given its importance in disease etiology (in particular in ulcerative colitis),
calling for more IBD immunogenetics studies in the future
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scientific publications (as shown by the steep increase of
publications per year in Fig. 1) and ultimately an improved
disease understanding. However, the variants identified in
GWAS still explain less than 30% of the estimated genetic
variance of IBD [40]. While IBD constitutes perhaps one
of the greatest success stories and role models in complex
disease genetics research, GWAS have also been quite
effective for a number of other complex diseases like
psoriasis [43–45], atopic dermatitis [46, 47] and primary
sclerosing cholangitis (PSC) [48, 49]. Combined analyses
of several of these immune-mediated diseases have even
revealed considerable overlap of susceptibility loci, point-
ing at true pleiotropy and shared disease etiologies beyond
CD and UC, while also showing complex disease-specific
patterns at shared loci as well as revealing disease-specific
loci [50, 51].
Interestingly, the genetic susceptibility factors for IBD
are, with a few exceptions (e.g. NOD2, TNFSF15, HLA),
the same in European-ancestry and East-Asian IBD
patients [41]. Similar results have been obtained for
other complex inflammatory diseases, such as sys-
temic lupus erythematosus [52]. Therefore, trans-
ethnic studies will clearly aid in identifying consistent
genetic risk loci for complex inflammatory diseases,
thus increasing also statistical power due to the lar-
ger sample sizes. The few differences in the genetic
risk maps may also help in pinpointing likely existing
different environmental factors in the countries
under study.
As previously indicated, GWAS studies focused on
SNPs with moderate to high allele frequencies in the
general population. A part of the so-called missing herit-
ability may however be found in rare variants with
larger effect sizes [53] for some diseases. Results of a
recent large-scale sequencing project of more than
2600 genomes and almost 13,000 exomes did not
support the idea that lower-frequency variants have a
major role in predisposition to type 2 diabetes [54].
For IBD, however, common and rare susceptibility
variants have been shown to even coexist in the
same genes, as is the case for NOD2 [34, 55, 56].
Figure 2a illustrates this wide range of IBD-relevant
variants concerning their penetrance and the genetic
disease complexity and provides an overview of the
identified genes from monogenic, fully penetrant
genes to those harboring common susceptibility vari-
ants. Rare and especially novel variants can best be
detected by DNA sequencing and the development of
NGS finally made this feasible for complex diseases.
Figure 2b depicts the discovery of IBD genes since
2001 employing the different technologies discussed
here and shows the great success of GWAS on the
one hand, but also the increasing relevance of NGS
during the past few years.
Application of NGS for complex diseases
The usage of NGS and especially exome sequencing for
Mendelian disorders proved to be extremely successful.
Even sequencing of just a single patient could lead to
the discovery of the genetic mutation responsible for the
disease by filtering the detected variants based on func-
tional consequence (e.g. missense, nonsense, splice-site
variants) and allele frequency in the general population,
for example in the data of the 1000 genomes project
[19, 57] or the Exome Aggregation Consortium (ExAC)
[20]. But when dealing with complex diseases, different
approaches need to be considered.
One possibility is the application of the GWAS
approach to NGS data, aiming for the identification of
significant differences between cases and controls.
Disease-associated common variants can best be de-
tected by GWAS and sequencing approaches have the
potential to complement this by discovering rare variant
associations, given that the necessary large sample sizes
are considered. However, with a decreasing allele fre-
quency, the power to detect genes or variants of interest
also decreases, if effect sizes are small to moderate.
Single marker association testing is therefore often
“underpowered” for rare variants with frequencies below
0.5% or even 0.1% minor allele frequency (MAF), since
the number of observations of such alleles is often not
large enough to achieve statistical significance due to
small sample sizes [58]. For example, observing an allele
once with 0.5 or 0.1% MAF with 99% probability requires
sequencing of at least 460 or 2300 individuals, respect-
ively. Assuming a disease-associated variant with 0.1%
MAF and an allelic odds ratio (OR) of 1.4, the sample size
(cases and controls with equal sized groups) required to
achieve 80% power is 540,000, given a disease prevalence
of 5% and a significance level of 5 × 10−8 [59]. However,
the commonly used significance level of 5 × 10−8 is valid
for approximately one million common tag SNPs
(MAF ≥ 5%) only if a linkage disequilibrium r2 < 0.8 for
pairs of tag SNPs is applied. With 0.1% MAF, we would
need a P-value threshold level of 1 × 10−8 and 3 × 10−7to
meet genome-wide and exome-wide significance (at
r2 < 0.8), respectively [60]. Several statistical methods
have been proposed in the past to perform case-control
studies with WES or WGS data, most of them using
variant aggregation approaches to address this issue.
The two main types of aggregation tests comprise bur-
den and variance component tests [58] or a mixture of
both. Burden tests [61, 62] compare the number of var-
iants in a certain region or gene between cases and
controls, while variance component tests (e.g. the
sequence-based kernel association test, SKAT [63]) can
distinguish between protective and risk variants in a
single gene, making them more powerful if the gene
possesses a mixture of protective and risk variants.
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Lee et al. [59] provide a comprehensive overview of
currently available algorithms.
The successful application of these tests is however lim-
ited by sample size, as sequencing studies involving WES
or WGS still require a significantly larger sample size than
a typical GWAS to identify significant rare variant associa-
tions [64]. Despite continuously decreasing prices for se-
quencing, case-control studies employing thousands of
a
b
Fig. 2 a Top: Range of IBD-relevant variants based on genetic complexity underlying the disease and variant penetrance. Bottom: Overview of
identified IBD genes ranging from monogenic to complex forms based on the highest known penetrance for each gene. For both NOD2 and
PRDM1, for example, both common and rare variants have been identified as disease-relevant in patients [110, 111]. b Timeline of gene discovery
for IBD [112–137]. Top graph shows cumulative number of genes separated by technology (log scale)
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individuals still remain a costly undertaking compared to
GWAS where the latest array generation (e.g. Global
Screening Array from Illumina with 700,000 variants) is
currently available for less than $40 per sample. The NGS
approach is therefore still restricted to large-scale se-
quencing centers, companies, healthcare providers (e.g.
Geisinger Health), consortia involving several institutes
and crowd-sourced approaches.
Therefore, the focus currently lies on the analysis of
unusual cases to find highly penetrant variants. Here,
one possibility is sequencing of large families with sev-
eral affected individuals to narrow the dataset down to
few candidate variants based on those shared by the
affected individuals [65]. Clustering of patients within a
pedigree may point to variants with larger effects on
disease compared to those identified in GWAS and even
monogenic forms of IBD. However, it can also simply in-
dicate the accumulation of a large number of common
susceptibility alleles in the pedigree [65] and exome se-
quencing may therefore not necessarily be successful.
Apart from multiplex families, the most informative
characteristics indicating the presence of a highly pene-
trant genetic cause are an early age of onset and very
severe course of disease. GWAS performed specifically for
pediatric IBD (age of onset <18 years) failed to clearly dis-
tinguish early onset from adult IBD, identifying known
IBD loci or exclusive pediatric loci that were later also
identified for adult IBD [66, 67]. There is great overlap be-
tween susceptibility genes identified for pediatric and
adult-onset IBD (more than 30 loci described [66]). Early-
onset cases of IBD, with a disease manifestation during
the first 10 years of life, often show a more severe disease
course with a higher risk of complications and a higher
frequency of indeterminate colitis (IC) diagnoses [68]. Pa-
tients classified as very-early-onset even develop the dis-
ease during the first 6 years of life. A large spectrum of
monogenic diseases, mainly immunodeficiencies, can also
present with IBD-like intestinal inflammation [69]. How-
ever, several studies have also identified shared genetic
factors underlying these monogenic, early-onset and
adult-onset IBD cases with rather oligogenic or polygenic
causes. Mutations in genes for the interleukin 10 receptor
(IL10R) subunit proteins [70] and the IL10 gene itself [71]
were shown to be responsible for several cases of severe
early-onset IBD (eoIBD). At the same time, IL10 was also
associated with adult-onset UC [72] and CD [39] in
GWAS. Other identified causes of eoIBD include a dele-
tion in ADAM17 (ADAM metallopeptidase domain 17)
[73] and mutations or deletions in the XIAP (X-linked
inhibitor of apoptosis) gene [74–76] in male patients.
Although the direct overlap between key genes associated
with IBD and IBD-like monogenic disorders is rather low,
the affected proteins often interact directly or indirectly
with each other and share common signaling cascades
that contribute to IBD etiology [69]. Results from mono-
genic forms therefore have the potential to give important
insights into mechanisms contributing to disease. An
excellent overview of the genetics of early- and very early-
onset forms of IBD is the review by Uhlig et al. [77].
Targeted resequencing of susceptibility regions has
also been applied for several immune diseases and has
identified additional rare, functional variants in suscepti-
bility genes, which were detected using common variants
in GWAS. For instance, gene resequencing for atopic
dermatitis identified low-frequency missense variants in
the GARP gene as significant contributors to disease risk
[78]. Perhaps not surprisingly, monogenic disease forms
of complex diseases—i.e. patients that carry variants
with very high penetrance—have not exclusively been
detected for IBD, but also for other diseases. For ex-
ample, monogenic forms of psoriasis caused by muta-
tions in CARD14 [79] were revealed through exome
sequencing of a family with early-onset psoriasis. Studies
of rare variants in Mendelian forms of disorders that are
symptomatically similar to systemic lupus erythematosus
(SLE) have highlighted pathways also playing a role in
the complex disease form. As another example, TREX1,
encoding for the three prime repair exonuclease 1, has
been associated with monogenic Aicardi-Goutières syn-
drome [80], a disease displaying phenotypic overlap with
SLE. More recently, 0.5% of SLE patients were shown to
also harbor mutations in this gene [81].
While sequencing of severe early-onset patient exomes
greatly facilitated the identification of novel, high pene-
trance variants, their discovery among the tens of thou-
sands of variants identified in an exome is still a major
challenge. Since the first exome studies that relied on al-
lele frequencies from the 1000 genomes pilot [82], several
large-scale sequencing studies for genomes and exomes
have been undertaken. Databases like EVS [83], ExAC
[20] and KAVIAR [84] now provide population-specific
allele frequencies from several thousands to more than
60,000 individuals that can be used for filtering of candi-
date variants. However, some of these databases are
“contaminated” with data from patients or yet unknown
patients of similar symptoms as the disease of interest, so
the data should be used with caution.
The interpretation of non-coding variants has proven
to be extremely challenging. The ENCODE project [85]
significantly facilitated the understanding of functional
elements in the human genome. However, the complex
analysis of these sites is not yet routinely carried out in
most projects. For exome data, the analysis of non-
coding variants is limited from the beginning, due to the
nature of the technology with exclusive enrichment of
exons and, in some cases, UTRs. Variants from exomes
therefore tend to be reduced to those that are most
likely to affect protein structure. Nonsense, start-loss,
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stop-loss and splice-site variants as well as frameshift
insertions and deletions (InDels) have rather clearly
defined effects on the protein and are present in com-
parably low numbers. The interpretation of sometimes
hundreds of rare missense variants represents a greater
challenge. Several in silico prediction tools are available
to identify those amino acid changes that most likely
affect protein structure. SIFT [86] and Polyphen-2 [87]
were the first widely used tools, more recently DANN
[88], CADD [89] and FATHMM [90] were introduced.
The latter promise improved accuracy and additionally
offer predictions for non-coding variants. Other tools
specifically focus on identifying splice-altering variants,
including those located farther away from the exon-
intron boundary [91, 92]. Genes also differ concerning
the amount of potentially disruptive genetic variation
they can tolerate, expressed for example by the residual
variation intolerance score (RVIS) [93]. The prediction
of the effect of a variant on the protein structure and
thereby its function is however only one of the levels
that need to be considered when aiming to detect
disease-relevant variants. Variants diminishing the func-
tion of a gene do not necessarily manifest as an ob-
servable phenotype. This can for example be due to
redundancy of the function in several genes, preventing
the deficiency of one from having an effect. Filtering and
priorization of variants based on these criteria can
already significantly reduce the number of candidates. In
some cases, this is sufficient to identify a likely causative
variant relying on the known function of a well charac-
terized gene or novel variants in a known disease gene.
In most cases, however, additional filtering is needed. In
general, it is helpful to analyze more than one individual
of a family, even when dealing with sporadic cases, since
this allows the identification of variants segregating with
the disease within the pedigree. For sporadic cases the
healthy parents can also be used to detect de novo muta-
tions in the patient. These filtering steps can, however,
still result in a number of variants remaining, without
being able to clearly identify the most likely candidate.
Novel genes that haven’t previously been implicated in
disease or even genes with an unknown function sub-
stantially complicate the search. The question then
arises, how to proceed with a handful of candidates with
a possible but unconfirmed pathogenic effect (variants of
unknown significance, VUS) that remain after filtering
with all available methods. Functional analyses, espe-
cially for genes that are not yet well characterized, can
be time-consuming and expensive.
The case of a family with Crohn’s disease and auto-
immunity in two children [94] nicely illustrates this
issue. Exome sequencing was performed and yielded sev-
eral candidates, among them a rare missense variant in
CTLA4 (Cytotoxic T lymphocyte-associated protein 4).
While it represented a likely candidate, it was also
present in the asymptomatic mother. This incomplete
penetrance, as well as other candidate variants, made in-
terpretation and priorization difficult. Also, heterozygous
CTLA-4 deficiency in mice does not induce a phenotype
[95], which made the role of the detected variant in
disease questionable. Additional evidence pointing to
CTLA4 finally emerged when variants were also identi-
fied in other patients with immune phenotypes [96, 97]
and functional studies were able to back the role of het-
erozygous CTLA4 variants in immune dysregulation.
The incomplete penetrance suggests that additional
modifying factors yet need to be revealed, requiring the
analysis of additional patients with CTLA-4 deficiency.
Developing infrastructure for data sharing
Reliably classifying disease-causing variants often in-
volves finding correlations between different, independ-
ent observations, i.e. patients or cohorts with similar
clinical phenotypes in which the same (or a functionally
related) variant has been observed. For very rare or pri-
vate variants only a second patient with the same symp-
toms and the same genetic variant is sufficient for
statistical proof of the original finding. Sources of infor-
mation are usually published studies and public data
repositories that need to be searched, manually or with
specifically set up local bioinformatics pipelines. How-
ever, the complexity of the data at hand (including
sometimes dozens of VUS for larger patient cohorts) as
well as the vast amount of sequences that is now rou-
tinely being generated and deposited, is calling for more
efficient and integrated approaches.
Several efforts exist that aim to specifically aggregate
relevant clinical data, including databases such as De-
cipher [98], HGMD [99] or ClinVar [100]. Complemen-
tary to these resources, projects are under way to better
link national infrastructures and communities. Of note
here are, for example, the Belgian “SymBioSys” (http://
www.kuleuven.be/symbiosys/) or the German “Var-
Watch” project (BMBF project ID01EK1506 [101]), both
targeting separate issues in the integration of NGS data
and clinical variants. The main goal of SymBioSys is to
leverage national NGS data and provide efficient access.
It does so by building a federated network across se-
quencing facilities, together with a generic interface that
helps in rapidly mining the data for identical variants or
study parameters. VarWatch, on the other hand, is fo-
cused directly on the clinical context and is designed to
function as both a repository and a “monitoring” tool.
Clinicians can submit their VUS, together with pheno-
typic information about the disease, and VarWatch will
continuously search for matching cases, both within its
own data repository as well as external resources.
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While these initiatives are potentially important build-
ing blocks towards generating comprehensive clinical re-
sources, they leave the larger issue of how to efficiently
access and integrate the globally accumulating informa-
tion about the genetics of individual patients and their
conditions unanswered. A solution that is finding strong
support amongst larger databases and bioinformatics
institutes is currently being developed by the “Global
Alliance for Genomics and Health” (GA4GH), an inter-
national consortium of clinicians and bioinformaticians
with the goal of providing standards and software for
sharing clinical data on a global scale. One product of
these activities has been the “Beacon” network, and in
extension “MatchMaker Exchange” (MME) [102]. The
focus of Beacon and MME is to provide a “connective
tissue” between various “information islands”, linking
databases through a common interface and enabling
simple, platform agnostic queries without having to cre-
ate huge aggregations of data. Databases connected to
the beacon network can easily be queried for the pres-
ence of specific variants. MME further extends this con-
cept, allowing users not only to find identical variants,
but also to include information about the clinical con-
text of the variant (such as observed phenotype). In
doing so, it can bring together clinicians and researchers
with patients whose variants are not strictly identical,
but potentially related on a functional level and thus fur-
ther help finding diagnoses. Figure 3 depicts the variant
filtering of one real-world example from our clinic for
trio exome sequencing. While the filtering steps are able
to reduce the number of variants from more than 67,000
to only 18 variants potentially of interest, it is still
difficult to select the best candidate among these VUS or
in limbo variants. One possible solution for this problem
is the usage of MME which can detect overlaps between
the VUS submitted by different scientists or clinicians
and establish contact between them, making it possible
to pinpoint the causative variant(s) and thus solve the
clinical case (statistical significant result through recur-
rent finding of very rare event).
It is also becoming increasingly clear that in addition
to efficient access to distributed variant information,
there is also a growing need for metadata standards to
describe clinical observations not only genetically, but
also phenotypically. While several vocabularies have
been proposed over the years, the ones in use – such as
the Unified Medical Language System (UMLS) [103] -
are focused more on syndromes and less so on the
Fig. 3 Course of a typical trio exome project yielding several VUS and benefit of MME for variant selection. Filter by mode of inheritance:
recessive or dominant; by variant consequence: missense, nonsense, splice-site, start-loss or stop-loss; by frequency: maximum minor allele
frequency of 1% in various databases (ExAC, EVS, in-house controls)
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symptoms a patient is presenting with. This information
however will likely be vital, especially when trying to
match rare variants and rare diseases with poor repre-
sentation in standard nomenclatures. A promising
solution has recently been proposed in the form of the
Human Phenotype Ontology (HPO) [104], a collection
of hierarchical, phenotypic descriptors organized in an
ontological network similar to the already well-established
sequence ontology (SO) [105] and gene ontology (GO)
[106]. In addition to providing a complementary nomen-
clature for clinicians to better characterize their findings,
the inherent network-like structure of the HPO also al-
lows to measure the distance between any two terms. This
enables more complex matching scenarios, for examples
when clinicians have used slightly different but related
terms or sets of terms to characterize their patients [107].
Future directions
Combination of methods
Apart from genome and exome sequencing, which we
focus on here, there are several other NGS applications
that we expect to increase in relevance as efforts are
concentrating on linking observed mutations to func-
tional consequences beyond putative coding changes. Of
great interest here are the detection of modulation in
gene activity, for which both the direct sequencing of
transcripts through RNAseq as well as the detection
of differentially methylated sites (DMS) by means of
bisulfite sequencing as proxy for regulation hold great
promise. A completely different but equally important line
of inquiry is the metagenomic sequencing of the host-
associated microbiome to detect possible correlations be-
tween the presence or absence of certain genera and dis-
ease, as has already been suggested for a decrease in
Bacteroides and Firmicutes and a reduced diversity of the
microbiota in IBD patients [108]. The combined applica-
tion of these multi-omics data has the potential to provide
an improved overall picture of the characteristics of a cer-
tain disease and therefore help to understand its molecu-
lar underpinnings. With sequencing costs further
decreasing, large case-control studies with sample sizes
comparable to GWAS are also slowly becoming a reality
and will help detect rare variant associations specifically
for complex diseases. The biggest challenge though re-
mains, identifying relevant environmental factors in com-
plex diseases. Genetics and other functional genomics
analyses may also help in hinting at the disease-causing
environmental factors.
Technological developments
WES and WGS allow for the accurate identification of
single-nucleotide variants (SNVs) and small InDels. For
the detection of large InDels, copy number variations
(CNVs) as well as genomic rearrangements, however,
deep sequencing and meticulous analyses are needed,
which are mostly not yet part of the common analysis
pipelines used in the majority of projects.
NGS is already being applied to the clinic for the diag-
nosis of certain diseases, mostly through deep sequen-
cing of gene panels. However, relevant variants still
require confirmation through Sanger sequencing due to
the generally lower quality of NGS data, so it is desirable
to further increase the quality of NGS in the near future.
New methods are continuously being developed to use
NGS for additional applications or to extract more infor-
mation from standard applications. 10X Genomics for ex-
ample offers an additional instrument (Chromium), which
is fully compatible with the workflows of available NGS
sequencers and enables large-scale phasing of variants and
structural variant detection from WGS and even WES as
well as single cell applications by generating synthetic long
reads. The Chromium instrument uses emulsion to parti-
tion DNA. Barcoding and amplification of smaller frag-
ments from the original larger fragments then takes place
in droplets called “GEMs” that include all necessary re-
agents, resulting in the small fragments stemming from
one larger molecule carrying the same barcode. These
“synthetic long reads” can therefore be linked over larger
regions of the genome. The workflow delivers ready-to
use libraries for sequencing and software for the analysis
and visualization is openly available.
Other companies opt for the development of new
sequencing technologies, often called “third-generation se-
quencers”. Pacific Biosciences performs single molecule,
real-time (SMRT) sequencing of DNA fragments using
immobilized DNA-polymerases and produces reads of
over 10,000 bp average length. Nanopore sequencers, like
those developed by Oxford nanopore, detect the DNA se-
quence of a single-stranded DNA molecule by passing it
through a protein pore and measuring a shift in voltage
that originates from interactions with the pore. However,
these single-molecule technologies are still too expensive
and not yet applicable for resequencing larger numbers of
complete human genomes.
Looking further into the future, several exciting new
technologies are on the horizon. Genia Technologies,
which was bought by Roche in 2014, is currently develop-
ing a nanopore-based sequencing technique with a focus
on diagnostic applications. First results have already been
published [109], showing promising proof-of-principle re-
sults. However, it will likely still take several years until
the method is ready for the market. Illumina is planning
the launch of a new semiconductor sequencer in 2017 as
part of their Project Firefly, but as of yet, no details have
been released to the public. GenapSys by Sigma Aldrich
promises a low-cost, portable sequencer with a purely
electronic sequencing chip, but more information is cur-
rently only available to its testers.
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Conclusions
The extraordinary progress in the development of
methods for genomic analysis during the past 15 years
and especially the breakthrough in NGS in the past
decade has led to an enormous increase in the under-
standing of the human genome and its relation to dis-
ease. Improved technologies continuously provide faster,
cheaper and more accurate results, allowing us to move
from gene panels to exomes to routinely sequencing
whole genomes in the clinic in the near future. It has
however become increasingly clear, that to make the
most of the large, complex datasets being generated,
scientists must work together more than ever, to achieve
the ultimate goal of translating genomic data into clinic-
ally actionable results that patients can directly profit
from. With the generation of genomics data continu-
ously becoming easier and cheaper, the interpretation of
the large amounts of data and the identification of the
relevant disease-causing environmental factors will re-
main the biggest challenges of the years to come.
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